CD4 News and Research

RSS

HIV alters SARS-CoV-2 immune response without affecting COVID-19 symptoms or outcomes

In a preprint paper published on the medRxiv server, a team of researchers from various institutions in South Africa, the UK, and Europe discuss how they determined the impact of HIV on the COVID-19 immune response in KwaZulu-Natal, South Africa, which is an area with very high HIV prevalence.

26 Nov 2020

BCG vaccination appears to trigger cross-reactive SARS-CoV-2-specific T cell response

Recently, researchers from the Monash University and Monash Medical Centre, Clayton, Victoria, Australia, investigated whether peptide sensitization using BCG can produce cross-reactive T cells specific to SARS-CoV-2. Their study is published on the preprint server, medRxiv.

24 Nov 2020

Mild COVID-19 disease may trigger long-term immunity

Researchers in the United States have conducted a study showing that individuals who have recovered from mild coronavirus disease 2019 (COVID-19) developed sustained protective immune memory against the causative agent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

24 Nov 2020

Research reveals T-cell abnormalities in severe COVID-19 cases

There is an idea within the coronavirus research field that there is some kind of T cell abnormality in critically ill COVID-19 patients, but specific details have not yet been clarified.

20 Nov 2020

SARS-CoV-2 immunity can last over six months, study finds

US-based scientists have released a study on preprint server bioRxiv*, titled “Immunological memory to SARS-CoV-2 assessed for greater than six months after infection,” contributing to the enormous research effort currently underway in this area.

19 Nov 2020

Most COVID-19 convalescent individuals have long-lasting memory T cell responses

Recently, researchers from the Huazhong University of Science and Technology, China, and the University of Duisburg-Essen, Germany, conducted a comprehensive analysis of memory T cell responses against SARS-CoV-2 in individuals who have recovered from COVID-19.

18 Nov 2020

COVID-19 during pregnancy can cause placental inflammation and impaired immunity

A new study conducted by a team of researchers at Johns Hopkins University, USA, has observed how pregnant women infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) show stunted antiviral immune responses.

18 Nov 2020

SARS-CoV-2 causes a unique cytokine storm, study finds

A new study published on the preprint server medRxiv* in November 2020 reports some of the unique elements of COVID-19-induced CRS and how understanding these distinctive characteristics of the disease could help in formulating specific interventions and therapies.

18 Nov 2020

Children's DTP vaccine may provide cross-immunity for COVID-19

He found that the viruses subject to pediatric vaccinations do not have cross-reactive epitopes for SARS-CoV-2, showing they cannot provide protection against COVID-19.

17 Nov 2020

Discovery of 'Achilles heel' in protein crucial to HIV virulence could lead to new class of drugs

The discovery of a potential "Achilles heel" in Nef, the protein that is crucial to HIV virulence and its capacity to trigger AIDS, paves the way for the development of a new class of drugs against the virus.

17 Nov 2020

Research uncovers a new underlying cause of heart attack

Heart attacks strike suddenly and have a range of different triggers. Researchers from Charité - Universitätsmedizin Berlin and the German Centre for Cardiovascular Research (DZHK) were able to uncover a further underlying cause.

10 Nov 2020

Exosome-mediated mRNA delivery generates broad immune response to multiple SARS-CoV-2 proteins

Recently, researchers from The Johns Hopkins University School of Medicine, Baltimore, MD, USA, and Capricor Therapeutics, Inc., Beverly Hills, CA, USA, described a new approach to SARS-CoV-2 vaccine development using exosomes to deliver mRNAs that encode the antigens from multiple structural proteins of the virus.

9 Nov 2020

Majority of population likely has pre-existing immunity to SARS-CoV-2, claim researchers

A team of researchers has conducted a study suggesting that the majority of the global population is likely to have pre-existing T-cell immunity to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent responsible for the coronavirus disease 2019 (COVID-19) pandemic.

9 Nov 2020

SARS-CoV-2 viral antigens found in non-pulmonary tissues in recovering patients

A team of researchers in Singapore, led by Dr. Joe Yeong, and Prof. Tony Kiat Hon Lim, have reported the presence of residual SARS-CoV-2 ribonucleic acid (RNA) – the virus' genetic material – in stool samples and gastrointestinal tissues from patients recovering from the coronavirus disease 2019 (COVID-19).

8 Nov 2020

SARS-CoV-2 T-cell immunity is retained for at least six months

Now, a new study published on the preprint server bioRxiv shows that functional SARS-CoV-2-specific T-cell responses are retained for six months following infection. However, the strength of this response depends on the clinical features of the primary infection.

3 Nov 2020

Study reveals seven “forms of disease” in COVID-19

In a study recently published in the top journal "Allergy", a team of MedUni Vienna scientists led by immunologist Winfried F. Pickl and allergologist Rudolf Valenta (both from the Center for Pathophysiology, Infectiology and Immunology) showed that there are seven "forms of disease" in COVID-19.

2 Nov 2020

Researchers report a novel approach to generate T-cells faster

Adoptively transferred T-cells can prolong survival and sometimes cure patients with advanced solid tumors. While promising, it can take months to generate the necessary T-cells to help these patients. Such slow speed makes this therapy impractical for most patients who need immediate treatment.

30 Oct 2020

Antiviral inhibitor DDX42 shows broad activity against Chikungunya, HIV and SARS-CoV-2

By exploiting type 1 interferon's ability to foster an antagonistic cellular environment for viral replication, a research group from France pinpointed DEAD-box RNA helicase DDX42 as an intrinsic inhibitor of HIV, but also other pathogenic viruses such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and Chikungunya virus.

29 Oct 2020

Lung biomarkers may predict severe COVID-19

Two University of New Mexico researchers postulate certain specific biomarkers' relevance in predicting the potential for progression to severe COVID-19 in a paper published on the preprint server bioRxiv*

27 Oct 2020

New technique could propel personalized cancer treatments

When it comes to defeating cancer, some immune cells are mightier than others. But even the best-trained eye and today's advanced scientific tools have trouble discerning the most powerful tumor-fighting cells from the rest.

23 Oct 2020

CD4 News and Research

HIV alters SARS-CoV-2 immune response without affecting COVID-19 symptoms or outcomes

BCG vaccination appears to trigger cross-reactive SARS-CoV-2-specific T cell response

Mild COVID-19 disease may trigger long-term immunity

Research reveals T-cell abnormalities in severe COVID-19 cases

SARS-CoV-2 immunity can last over six months, study finds

Most COVID-19 convalescent individuals have long-lasting memory T cell responses

COVID-19 during pregnancy can cause placental inflammation and impaired immunity

SARS-CoV-2 causes a unique cytokine storm, study finds

Children's DTP vaccine may provide cross-immunity for COVID-19

Discovery of 'Achilles heel' in protein crucial to HIV virulence could lead to new class of drugs

Research uncovers a new underlying cause of heart attack

Exosome-mediated mRNA delivery generates broad immune response to multiple SARS-CoV-2 proteins

Majority of population likely has pre-existing immunity to SARS-CoV-2, claim researchers

SARS-CoV-2 viral antigens found in non-pulmonary tissues in recovering patients

SARS-CoV-2 T-cell immunity is retained for at least six months

Study reveals seven “forms of disease” in COVID-19

Researchers report a novel approach to generate T-cells faster

Antiviral inhibitor DDX42 shows broad activity against Chikungunya, HIV and SARS-CoV-2

Lung biomarkers may predict severe COVID-19

New technique could propel personalized cancer treatments

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News